Dr. Charles Truillet is a biomedical imaging biologist specializing in theranostic strategies that integrate early cancer detection with treatment. His research centers on developing innovative therapeutic strategies that combine molecular imaging with targeted drug delivery to optimize the spatiotemporal control of treatments and improve prediction of therapeutic response. This approach complements his investigation into the complex interplay between radioligand therapy, tumor cells, and the immune system, with particular emphasis on how combination therapies can reshape these interactions to enhance anti-tumor efficacy.

He earned his PhD in nanosciences in 2013, contributing to the development of the AGuIX nanotechnology platform—now in Phase 3 clinical trials—for therapeutic and imaging applications. During his postdoctoral training at UCSF, Dr. Truillet conducted pioneering work on immunoPET imaging and protein-based ligand pharmacokinetics, notably targeting PD-L1 to measure immune checkpoint expression in vivo.

Since joining the CEA in 2017, he has led research on novel imaging and internal radiotherapy approaches designed to enhance anti-tumor immune responses. As head of the ONCO group at BioMaps since 2020, Dr. Truillet has led and supported interdisciplinary collaborations, driving translational research at the crossroads of immunology, oncology, and molecular imaging.